When Scored Canine Tablets Exceed 15% w/w API in Direct Compression

Enrofloxacin HCl is incorporated into companion animal tablets on production-scale rotary presses equipped with B-tooling. Direct compression blends containing 10–30% w/w enrofloxacin HCl—equivalent to roughly 22.7 mg, 68 mg, and 136 mg enrofloxacin base per finished tablet—require conditioning of the blend to a loss on drying of 1.0–2.0% before compression. On a 16-station press running at 40–60 rpm, blends above 15% w/w API exhibit Carr index values above 28 and require 0.5–1.0% w/w colloidal silicon dioxide and 2.0% sodium stearyl fumarate to maintain ejection force below 10 kN. Granular forms are produced by top-spray fluidized bed granulation with inlet air 55–65 °C, bed temperature 28–34 °C, and spray rate 10–20 g/min/kg of dry powder. The dried granules are milled through a 0.8 mm screen and compressed at 8–18 kN to hardness 60–90 N and friability below 0.8%. Batch-to-batch variance in granule moisture above 2.5% w/w has been associated with edge capping at dwell times below 12 ms, so moisture is monitored by near-infrared before tableting. Release testing follows USP <905> Uniformity of Dosage Units with acceptance value not exceeding 15, USP <711> Dissolution using Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl at 37 ± 0.5 °C, and USP <921> Karl Fischer water determination. Process equipment qualification follows 21 CFR 211.65 and 21 CFR 211.67 for cleaning validation, while stability protocols reference ICH Q1A(R2) zone II long-term storage at 25 °C/60% RH and intermediate 30 °C/65% RH. Terminal finished dose forms include meat-flavored scored tablets at 22.7 mg, 68 mg, and 136 mg base equivalent, some with film coating applied in a perforated pan at 38–42 °C product temperature. The scored form is compounded to allow halved dosing in small dogs and cats, and the coating is non-enteric but light-protective because the hydrochloride salt is photolabile in solution and at tablet surfaces under prolonged illumination.

Across commercial broiler and turkey integration units, enrofloxacin HCl is formulated as a 10% w/v oral solution for drinking-water medication, with a nominal concentration of 100 mg/mL enrofloxacin base equivalent. The solution is prepared at 20–25 °C using purified water; pH is adjusted to 3.5–4.5 with dilute sodium hydroxide or hydrochloric acid before the hydrochloride salt is added under low-shear propeller mixing at 200–400 rpm. This pH window prevents precipitation of the weakly basic drug at refrigerated temperatures while limiting acid-catalyzed hydrolysis of the piperazinyl ring. The medicated water dose is typically 10 mg/kg body weight per day for 3–5 days, diluted to a drinking-water concentration of 50 ppm in many flock protocols, though actual concentrations depend on daily water intake and local veterinary authorization. Nitrogen sparging at 0.5–1.0 L/min limits oxidative discoloration; the bulk solution is filled into amber PET bottles or Type III glass containers with headspace below 5% of nominal volume. Release testing uses Ph. Eur. 2.2.29 liquid chromatography and Ph. Eur. 2.2.32 loss on drying; container suitability follows USP <660>. Residue control in edible tissues is governed by Commission Regulation (EU) No 37/2010, with enrofloxacin plus ciprofloxacin as marker residue and poultry muscle MRL at 100 µg/kg, liver at 200 µg/kg, and kidney at 300 µg/kg. Withdrawal periods in poultry products are commonly set at 7 days for meat and offal, but local registration dossiers may impose longer intervals. Terminal finished pack sizes include 100 mL, 250 mL, 1 L, and 5 L containers with anti-tamper caps and graduated dosing chambers.

What Limits the Deliquescence Risk in Swine Water-Soluble Granules?

Water-soluble granules for swine herd medication are manufactured at 5% w/w and 10% w/w base-equivalent enrofloxacin using a lactose monohydrate–maltodextrin carrier system. For a 10% formulation, the carrier-to-API ratio is kept near 8:1, and polyvinylpyrrolidone K30 is added at 1.5–2.0% w/w as a binder to produce free-flowing granules. Deliquescence is the main failure mode because enrofloxacin HCl and lactose both absorb atmospheric moisture at relative humidity above 60%; therefore, the dried granules are specified with loss on drying below 1.5% and are packaged in aluminum-foil laminate with a water vapor transmission rate below 0.1 g/m²/day at 38 °C/90% RH. High-shear granulation proceeds at impeller speed 200–300 rpm and chopper speed 1500 rpm with 12–18% w/w purified water added as granulating fluid; the wet mass is discharged through a 2.0 mm screen and dried in a fluid bed at 50–60 °C to final moisture 1.0–1.5%. The dried granules are sieved to 180–850 µm, and fines below 180 µm are recycled to the next batch at no more than 20% of dry-mix weight to avoid dissolution lag. Release testing is conducted according to USP <921> for water content, Ph. Eur. 2.9.40 for particle-size distribution, and 21 CFR 211.165 for assay and related substances. Cleaning validation follows 21 CFR 211.67 with rinse-sampling limits calculated from a 10 ppm carry-over criterion. Terminal finished pack types are 250 g, 500 g, and 1 kg foil sachets and 5 kg pails with a desiccant canister.

Injectable Solution Sterilization Windows for Bovine and Porcine Formulations

Injectable enrofloxacin HCl is prepared at 100 mg base/mL in Water for Injection. The hydrochloride salt is dissolved at 20–25 °C, and pH is adjusted with sodium hydroxide to 3.8–4.5 because the solubility of the free base drops sharply above pH 5.0, while pH below 3.5 increases injection-site irritation and acid hydrolysis of the quinolone ring. The bulk solution is sparged with nitrogen to maintain dissolved oxygen below 0.5 ppm and is filtered through a 0.45 µm polyethersulfone prefilter followed by a 0.22 µm PVDF sterilizing-grade membrane. Terminal sterilization in a saturated steam autoclave is performed at 121 °C for 15 min, with a minimum F0 of 12 min for vial formats up to 100 mL; larger 250 mL vials require cycle development to achieve an F0 of at least 15 min at the cold spot. On a 12-head piston filling line, headspace oxygen above 3% has been associated with color shift in accelerated stability at 40 °C/75% RH for 6 months, so vials are flushed with nitrogen before stopper placement. The fill volume is controlled with occasional in-process checkweighing at ±1.0% of nominal volume. Compliance testing includes USP <1> Injections, USP <85> Bacterial Endotoxins with a calculated action limit below 0.15 EU/mg for this parenteral water-based product category, USP <788> Particulate Matter in Injections, and 21 CFR 211.167 sterility testing. Finished terminal forms include 50 mL, 100 mL, and 250 mL amber Type I borosilicate glass vials sealed with chlorobutyl rubber stoppers and aluminum flip-off caps.

Compounded for avian and reptile patients, enrofloxacin HCl capsules in microdosed strengths require geometric dilution with lactose monohydrate to achieve content uniformity within ±10% of label claim. The API fraction in these small-batch capsules is typically 0.5–15% w/w, corresponding to 2–25 mg enrofloxacin base per capsule, and each batch is triturated in a glass mortar with a pre-blend of the diluent before being transferred to a semi-automatic capsule filler for size 3 or 4 gelatin capsules. Fill weight is checked on an analytical balance with a tolerance of ±5 mg for total fill weights below 50 mg; capsule-to-capsule weight drift above this tolerance has been traced to static charge on the gelatin shell in low-humidity compounding rooms below 30% RH. The compounded capsules are packaged in amber glass vials with desiccant, and beyond-use dating is assigned according to USP <795> nonsterile compounding criteria. Published data for this specific exotic-animal capsule configuration is limited, so each release relies on Ph. Eur. 2.9.5 uniformity of mass and USP <795> documentation rather than a commercial pharmacopeial monograph. Terminal finished types include individual patient capsules for parrots, ferrets, and reptiles, as well as capsule contents used to prepare oral suspensions immediately before administration.